Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.

被引：0
|
作者：
Fountzilas, Christos
Rosario, Spencer
Withers, Henry G.
Mukherjee, Sarbajit
Bajor, David L.
Saltzman, Joel N.
Wang, Chong
Attwood, Kristopher
Knudsen, Erik S.
Witkiewicz, Agnieszka K.
Iyer, Renuka V.
Boland, Patrick M.
机构：
[1] Roswell Pk Comprehens Canc Ctr, Div GI Med, Dept Med, Buffalo, NY USA
[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[3] Case Western Reserve Univ, Case Comprehens Canc Ctr, Univ Hosp, Seidman Canc Ctr, Cleveland, OH USA
[4] Cleveland Clin, Cleveland, OH USA
[5] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
178
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF CAPECITABINE AND IRINOTECAN (CAPIRI) IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, Adda
    Smaili, Farida
    ANNALS OF ONCOLOGY, 2011, 22 : v99 - v99
  • [32] Prognostic factors of patients (pts) with salvage-line metastatic colorectal cancer (mCRC)
    Bando, Hideaki
    Oki, Eiji
    Takeda, Yuriko
    Misumi, Toshihiro
    Suzuki, Motoko
    Wakabayashi, Masashi
    Yamazaki, Kentaro
    Grothey, Axel
    Mayer, Robert J.
    Li, Jin
    Andre, Thierry
    Shi, Qian
    De Gramont, Aimery
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 115 - 115
  • [33] Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).
    Vincenzi, Bruno
    Loupakis, Fotios
    Bianchi, Andrea Sartore
    Russo, Antonio
    Mannavola, Francesco
    Perrone, Giuseppe
    Cremolini, Chiara
    Rossini, Daniele
    Ongaro, Elena
    Bonazzina, Erica
    Dell'Aquila, Emanuela
    Imperatori, Marco
    De Maglio, Giovanna
    Falcone, Alfredo
    Santini, Daniele
    Onetti-Muda, Andrea
    Siena, Salvatore
    Aprile, Giuseppe
    Tonini, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC)
    Abid, Haisam
    Szabo, Aniko
    Taylor, Bradley W.
    Shreenivas, Aditya V.
    Chakrabarti, Sakti
    Kamgar, Mandana
    Thomas, James P.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [35] Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib.
    Lafky, J. M.
    Bot, B. M.
    Morlan, B. W.
    Anderson, S. K.
    Kimlinger, T. K.
    Halling, T. M.
    Kumar, S.
    Reynolds, J. T.
    Stella, P. J.
    Dakhil, S. R.
    Loui, W. S.
    Alberts, S. R.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Utilization and cost of CPT-11 (C) in elderly previously treated metastatic colorectal cancer (MCRC) patients (pts).
    Eng, C
    Zhao, L
    Shih, YCT
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 266S - 266S
  • [37] Outcomes of long responders chemorefractory metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib: a single institution experience
    Sforza, V.
    Capasso, A.
    Nappi, A.
    Cardone, C.
    Martini, G.
    Ferrara, M. L.
    Napolitano, S.
    Vitiello, P.
    Vitale, P.
    Zanaletti, N.
    De Vita, F.
    Orditura, M.
    Troiani, T.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [39] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 250 - 251
  • [40] Predicting overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT): The British Columbia Cancer Agency (BCCA) mCRC score
    Chen, Leo
    Gresham, Gillian
    Cheung, Winson Y.
    Kennecke, Hagen F.
    Renouf, Daniel John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345